TABLE 2.
Stratified analysis of VTE prophylaxis quality by VTE risk category (Moderate vs. High).
| Indicators | Original groups (n = 1813) | Matched groups (n = 1190) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline group (n = 514) | Pilot intervention group (n = 664) | Pharmacist intervention group (n = 635) | Chi-square value | P value | Cramér’s V, 95% CI | Corrected P-value | Baseline group (n = 445) | Pilot intervention group (n = 425) | Pharmacist intervention group (n = 320) | Chi-square value | P value | Cramér’s V, 95% CI | Corrected P-value | |
| Pharmacological prophylaxis implementation rate (%) | ||||||||||||||
| Moderate risk of VTE | 25.9 | 31.8 | 32.3 | 0.8 | 0.155 | | | 28.6 | 35.4 | 30.9 | 1.0 | 0.207 | | |
| High risk of VTE | 76.7 | 76.6 | 75.6 | 1.0 | 0.888 | | | 78.1 | 79.1 | 79.6 | 0.9 | 0.861 | | |
| Mechanical prophylaxis implementation rate (%) | ||||||||||||||
| Moderate risk of VTE | 40.1 | 67.8 | 73.1 | 0.4 | <0.001 | 0.279, 95% CI [0.236, 0.318] | <0.001 | 42.9 | 64.0 | 69.9 | 0.5 | <0.001 | 0.226, 95% CI [0.171, 0.280] | <0.001 |
| High risk of VTE | 81.0 | 88.3 | 90.2 | 0.6 | 0.033 | 0.091, 95% CI [0.045, 0.137] | 0.100 | 81.9 | 85.7 | 90.9 | 0.6 | 0.095 | | |
| Combined prophylaxis implementation rate (%) | ||||||||||||||
| Moderate risk of VTE | 20.3 | 25.8 | 26.5 | 0.8 | 0.128 | | | 21.7 | 28.6 | 26.0 | 0.9 | | | |
| High risk of VTE | 70.7 | 70.3 | 69.5 | 1.0 | 0.895 | | | 71.4 | 71.4 | 70.5 | 1.0 | >0.999 | | |
| Standardized prophylaxis implementation rate (%) | ||||||||||||||
| Moderate risk of VTE | 46.3 | 73.9 | 78.9 | 0.4 | <0.001 | 0.288, 95% CI [0.244, 0.330] | <0.001 | 50.3 | 71.0 | 74.8 | 0.5 | <0.001 | 0.218, 95% CI [0.163, 0.272] | <0.001 |
| High risk of VTE | 76.9 | 76.7 | 76.1 | 1.0 | 0.888 | | | 78.3 | 79.4 | 80.0 | 0.9 | 0.861 | | |
VTE: venous thromboembolism; CI: confidence interval.